Vortioxetine-Related Call–Fleming Syndrome

Moodliar, Seshni; Naguy, Ahmed; AlKhadhari, Sulaiman

doi:10.1097/mjt.0000000000001082

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was also a report relating to a case of Call-Fleming syndrome or Reversible Cerebral Vasoconstriction Syndrome (RCVS), which arose in a twenty-year-old woman seven weeks after vortioxetine introduction. The presentation was somewhat aspecific, with features of meningism (headache, photophobia), strokelike motor deficits (hemiparesis and dysarthria) and intracranial hypertension (projectile vomiting) and completely resolved in three weeks with vortioxetine discontinuation and introduction of nimodipine 120 mg/day [142]. One report refers to two cases of Meige syndrome (bilateral orofacial dystonia with perioral dyskinesia and blepharospasm), which occurred in two sisters, both ten days after vortioxetine introduction and resolved a few days after vortioxetine discontinuation [143].…”

Section: Descriptive Observational Studiesmentioning

confidence: 99%

The Role of Vortioxetine in the Treatment of Depressive Symptoms in General Hospital Psychiatry: A Case-Series and PRISMA-Compliant Systematic Review of the Literature

Weiss,

Pacciardi,

D’Alessandro

et al. 2024

JCM

View full text Add to dashboard Cite

Depressive symptoms are a customary finding in hospitalized patients, particularly those who are undergoing long hospitalizations, underwent major surgical procedures or suffer from high levels of multimorbidity and frailty. The patients included in this case series shared high degrees of frailty-complexity and were evaluated within the ordinary consultation and liaison psychiatry service of the University Hospital in Pisa, Italy, from September 2021 to June 2023. Patients were administered at least one follow-up evaluation after a week and before discharge. To relate this case series to the extant literature, a comprehensive systematic review of vortioxetine safety and efficacy was performed. None of the six patients included developed serious safety issues, but one patient complained of mild-to-moderate nausea for some days after the vortioxetine introduction. Five out of six patients exhibited at least a slight clinical benefit as measured by the clinical global impression scale. Of the 858 entries screened via Scopus and Medline/PubMed, a total of 134 papers were included in our review. The present case series provides preliminary evidence for vortioxetine’s safety in this healthcare domain. The literature reviewed in this paper seems to endorse a promising safety profile and a very peculiar efficacy niche for vortioxetine in consultation and liaison psychiatry.

show abstract

Section: Descriptive Observational Studiesmentioning

confidence: 99%